title: Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
abstract: We treated 191 patients with histologically proved locally advanced stage (T3 or T4) and/or metastatic prostate cancer with a biodegradable depot formulation of a luteinizing hormone-releasing hormone analogue (Zoladex). After an initial increase in serum testosterone in week 1 of therapy a continuous decrease of testosterone to castrate levels was obtained. With a monthly injection of the luteinizing hormone-releasing hormone analogue 4 patients (2 per cent) experienced a transient increase in bone pain, 1 had ureteral obstruction and 1 suffered paraplegia during the first few weeks of therapy. Over-all objective and subjective responses were similar to those obtained by castration or estrogen therapy. The absence of local and systemic (long-term) side effects proves the validity of this approach for patients with advanced prostatic cancer.
authors.affiliation: Department of Urology, Sint Radboud University Hospital, Nijmegen, The Netherlands.
authors.forename: F M
authors.initials: FM
authors.lastname: Debruyne
authors.forename: L
authors.initials: L
authors.lastname: Denis
authors.forename: G
authors.initials: G
authors.lastname: Lunglmayer
authors.forename: C
authors.initials: C
authors.lastname: Mahler
authors.forename: D W
authors.initials: DW
authors.lastname: Newling
authors.forename: B
authors.initials: B
authors.lastname: Richards
authors.forename: M R
authors.initials: MR
authors.lastname: Robinson
authors.forename: P H
authors.initials: PH
authors.lastname: Smith
authors.forename: E H
authors.initials: EH
authors.lastname: Weil
authors.forename: P
authors.initials: P
authors.lastname: Whelan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D017273:Goserelin; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
chemical_list: D017273:Goserelin; D013739:Testosterone; D002064:Buserelin